

## Literatura ACTA MEDICINAE 7/2018 Pneumologie

- 2 **Biologická léčba nemalobuněčného karcinomu plic – současnost a výhledy**  
prof. MUDr. Jana Skříčková, CSc. | MUDr. Ondřej Venclíček | MUDr. Bohdan Kadlec | MUDr. Marcela Tomášková | MUDr. Lenka Jakubíková | MUDr. Jana Špeldová Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
- 2 **Nemalobuněčný karcinom plic ROS1 pozitivní, léčený crizotinibem – kazuistika**  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 2 **Pembrolizumab v první linii léčby nemalobuněčného karcinomu plic – kazuistiky**  
MUDr. Libor Havel Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha  
doc. MUDr. Radoslav Matěj, Ph.D. Oddělení patologie a národní referenční laboratoř TSE-CJN, 1. LF UK a Thomayerova nemocnice, Praha
- 3 **Pembrolizumab v první linii léčby nemalobuněčného karcinomu plic**  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 3 **Deficit  $\alpha_1$ -antitrypsinu**  
MUDr. Jan Chlumský, Ph.D. Pneumologická klinika, 1. LF UK a FTN, Praha
- 3 **Triple terapie u chronické obstrukční plicní nemoci**  
doc. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie a hrudní chirurgie Nemocnice Na Bulovce a 3. LF UK, Praha
- 3 **CHOPN – účinná bronchodilatační léčba – kazuistika**  
MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha
- 3 **Stručné souvislosti vakcinace proti pneumokokovi u nemocných s CHOPN a bronchiálním astmatem**  
MUDr. Pavel Turčáni Klinika nemocí plicních a tuberkulózy FN a LF MU, Brno
- 4 **Biologicky cílená léčba sarkoidózy – kazuistiky**  
MUDr. Lýdia Žarnayová | MUDr. Monika Žurková, Ph.D. | prof. MUDr. Vítězslav Kolek, CSc.  
Klinika plicních nemocí a tuberkulózy, LF UP a FN Olomouc
- 4 **CHOPN – kardiální pacient – kombinace bronchodilatancí – studie CLAIM**  
MUDr. Jan Beneš Klinika kardiologie, Institut klinické a experimentální medicíny, Praha
- 4 **Účinnost duální bronchodilatační léčby (indakaterol/glykopyrronium) na snížení plicní hyperinflace a následné zlepšení plnění komor u pacientů s CHOPN – komentář ke studii CLAIM**  
MUDr. Milan Sova, Ph.D. Klinika plicních nemocí a TBC, FN Olomouc
- 5 **Význam lehkých exacerbací CHOPN**  
MUDr. Jaromír Zatloukal, Ph.D. Klinika plicních nemocí a tuberkulózy, FN a LF UP Olomouc
- 5 **Bronchiektazie – dělení, diagnostika a léčba**  
MUDr. Petr Jakubec, Ph.D. Klinika plicních nemocí a tuberkulózy FN a LF UP, Olomouc
- 5 **(Ne)novinky v léčbě idiopatické plicní fibrózy**  
MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 5 **Současný pohled na diagnostický význam vydechovaného oxidu dusnatého**  
doc. MUDr. Petr Čáp, Ph.D. Centrum alergologie a klinické imunologie Nemocnice Na Homolce, Praha
- 6 **Biomarkery a biologická léčba bronchiálního astmatu**  
MUDr. Irena Krčmová, CSc. | MUDr. Jakub Novosad, Ph.D. Ústav klinické imunologie a alergologie FN Hradec Králové  
MUDr. Vratislav Sedlák, Ph.D. Plicní klinika FN Hradec Králové a LF UK, Hradec Králové
- 6 **Proč očkovat proti viru o velikosti 80 nm**  
MUDr. Ivana Čierna Peterová Pneumologická ambulance, Brandýs nad Labem

# Biologická léčba nemalobuněčného karcinomu plic – současnost a výhledy

prof. MUDr. Jana Skříčková, CSc. | MUDr. Ondřej Venclíček | MUDr. Bohdan Kadlec | MUDr. Marcela Tomíšková | MUDr. Lenka Jakubíková | MUDr. Jana Špeldová Klinika nemocí plicních a tuberkulózy LF MU a FN Brno

- Dušek, L. – Malúšková, D. – Mužík, J., et al.: Epidemiologie zhoubných nádorů plic, průdušnice a průdušek v České republice. *Onkologická Revue speciál; Současné trendy v léčbě karcinomu plic*, 2016, 8, s. 7–11.
- Travis, W. D. – Brambilla, E. – Noguchi, M., et al.: International association for the study of lung cancer /American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol*, 2011, 6, s. 244–285.
- Laskin, J. J. – Sandler, A. B.: State of the art in therapy for non-small cell lung cancer. *Cancer Invest*, 2005, 23, s. 427–442.
- Paz-Ares, L. – de Marinis, F., et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. *Lancet Oncol*, 2012, 13, s. 247–255.
- Skříčková, J. – Kolek, V., et al.: *Základy moderní pneumoonkologie*. Maxdorf, Praha, 2017.
- Lynch, T. J. – Bell, D. W. – Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*, 2004, 350, s. 2129–2139.
- Duffield, E. L. – Watkins, C. L. – Armour, A. A., et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *New Eng J Med*, 2009, 361, s. 947–957.
- Douillard, J. – Ostoros, G. – Cobo, M., et al.: Efficacy, safety and tolerability results from a phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients (PTS) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). *Lung Cancer*, 2013, 80, s. 31.
- Skříčková, J. – Bortlíček, Z. – Hejduk, K., et al.: Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients. *Eur Respir J Munich*, 2014, 44, s. 1-1.
- Rosell, R. – Carcereny, E. – Gervais, R., et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EUR-TAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 239–246.
- Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.: Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*, 2005, 353, s. 123–132.
- Yang, J. C. H. – Schuler, M. – Yamamoto, N., et al.: LUX-Lung 3: a randomized, open-label, Phase III study of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30, suppl., abstrakt LBA7500.
- Wu, Y. L. – Zhou, C. – Hu, Ch.-P., et al.: LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. At American Society of Clinical Oncology, Chicago, June 2, 2013. *J Clin Oncol*, 2013, 31, suppl., abstrakt 8016.
- Yang, J. C. – Wu, Y. L. – Schuler, M., et al.: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol*, 2015, 16, s. 141–151.
- Park, K. – Tan, E. – Zhank, L., et al.: Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7). ESMO Asia 2015, abstrakt LBA2\_PR, prezentováno 20. 12. 2015. Dostupné z: <https://slide.ctimeetingtech.com/library/esmo/browse/itinerary/5225/2015-12-20#2y6N0cj>, vyhledáno 18. 1. 2016.
- Mok, T. S. – Wu, Y. L. – Ahn, M. J., et al.: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med*, 2017, 376, s. 629–640.
- Soria, J. C., et al.: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*, 2017, 377, s. 1–13.
- Sequist, L. V. – Soria, J. C. – Camidge, D. R.: Update to rociletinib data with the RECIST confirmed response rate. *N Engl J Med*, 2016, 374, s. 2296–2297.
- Lee, J. S. – Park, K. – Han, J. Y., et al.: 425PD Clinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC. *Ann Oncol*, 2015, 26, suppl. 9, s. ix125–147.
- Havel, L.: Tyrosinkinázové inhibitory EGFR třetí generace cílí na mutaci T790M v léčbě nemalobuněčného karcinomu plic. *Onkol Revue*, 2018, 5, s. 1–9.
- Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- Wong, D. W. – Leung, E. L. – So, K. K., et al.: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer*, 2009, 115, s. 1723–1733.
- Shaw, A. T. – Solomon, B.: Targeting anaplastic lymphoma kinase in lung cancer. *Clin Cancer Res*, 2011, 17, s. 2081–2065.
- Takeuchi, K. – Choi, Y. L. – Togashi, Y., et al.: KIF5B-ALK, a novel fusion oncoprotein identified by an immunohistochemistry based diagnostic system for ALK-positive lung cancer. *Clin Cancer Res*, 2009, 15, s. 3143–3149.
- Shaw, A. T. – Yeap, B. Y. – Solomon, B. J., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol*, 2011, 12, s. 1004–1012.
- Shaw, A. T. – Kim, D. W. – Mehra, R., et al.: Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med*, 2014, 370, s. 1189–1197, DOI: 10.1056/NEJMoa1311107.
- Reck, M.: Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. 2013 ASCO Annual Meeting. *J Clin Oncol*, 2013, 31, suppl., abstrakt LBA8011.
- Hanna, N.: LUME-Lung 2: A multicentre, randomized, double-blind, phase III study of nintedanib plus pemetrexed vs. placebo plus pemetrexed in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. At American Society of Clinical Oncology, Chicago, June 2, 2013. *J Clin Oncol*, 2013, 31, suppl., abstrakt 8034.
- Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 2415.
- Thatcher, N. – Hirsch, F. R. – Szczesna, A., et al.: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus nectinmab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). *J Clin Oncol*, 2014, 32, s. 5s, suppl.; abstrakt 8008.
- Perol, M. – Ciuleanu, T. E. – Arrieta, O., et al.: REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. *J Clin Oncol*, 2014, 32, s. 5s, suppl., abstrakt LBA8006.
- Novello, S. – Mazières, J. – Oh, I.-J., et al.: Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. *Ann Oncol*, dostupné z: <https://doi.org/10.1093/annonc/mdy121>, vyhledáno 10. 5. 2018.
- Peters, S. – Camidge, R. – Shaw, A. T., et al.: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med*, 2017, 377, s. 829–838, DOI: 10.1056/NEJMoa1704795.
- Seto, T. – Kato, T. – Nishio, M., et al.: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (J025567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncol*, 28. 8. 2014, [http://dx.doi.org/10.1016/S1470-2045\(14\)70381-X](http://dx.doi.org/10.1016/S1470-2045(14)70381-X).
- Mok, T. S. – Wu, Y. L. – Ahn, M.-J., et al.: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med*, 2017, 376, s. 629–640.
- Papadimitrakopoulou, V. – Lee, J. J. – Wistuba, I. I., et al.: The BAT-TLE-2 Study: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. *J Clin Oncol*, 1. 8. 2016, pii, JCO660084. Epub před tiskem.

## Nemalobuněčný karcinom plic ROS1 pozitivní, léčený crizotinibem – kazuistika

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- Shaw, A. T., et al.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*, 2014, 371, s. 1963–1971.
- SPC přípravku XALKORI, 2017. SPC XALKORI.
- NCCN, 2017. *Non-Small Cell Lung Cancer*. Version 8.2017 NCCN Guidelines.
- Hanna, N., et al.: Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*, 2017, 35, s. 3484–3515.
- Modrá kniha České onkologické společnosti, 24. aktualizace, 2018. Dostupné z: <https://www.jlinkos.cz/lekar-a-multidisciplinari-tym/diagnostika-a-lecba/modra-kniha-cos/aktualni-vydani-modre-knihy/>, vyhledáno 8. 6. 2018.

## Pembrolizumab v první linii léčby nemalobuněčného karcinomu plic – kazuistika

MUDr. Libor Havel Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha

doc. MUDr. Radoslav Matěj, Ph.D. Oddělení patologie a národní referenční laboratoř TSE-CJN, 1. LF UK

a Thomayerova nemocnice, Praha

- Lopes, G., et al.: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)  $\geq$  1%: Open-label, phase 3 KEYNOTE-042 study. *J Clin Oncol*, 2018, 36, suppl., abstrakt LBA4.
- Gandhi, L., et al.: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *NEJM*, 16. 4. 2018.
- Paz-Ares, L.: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (chemo) with or without pembrolizumab (pembro) for patients (pts) with metastatic squamous (sq) non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2018, 36, suppl., abstrakt 105.

# Pembrolizumab v první linii léčby nemalobuněčného karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 **Garon, E. B. – Rizvi, N. A. – Hui, R., et al.:** Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*, 2015, 372, s. 2018–2028.
- 2 **Hui, R. – Gandhi, L. – Costa, E. C., et al.:** Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). *J Clin Oncol*, 2016, 34, suppl, abstrakt 9026.
- 3 **Reck, M. – Rodriguez-Abreu, D. – Robinson, A. G., et al.:** Pembrolizumab versus chemotherapy for PD-L1-positive non small cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.
- 4 **Langer, C. J. – Gadgeel, S. M. – Borgha, H., et al.:** Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol*, 2016, 17, s. 1497–1508.
- 5 **Leigh, N. B. – Hellmann, M. D. – Hui, R., et al.:** KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. 2017 ASCO Annual Meeting. Poster Discussion Session (Board #337). *J Clin Oncol*, 2017, 35, suppl, abstrakt 9011.
- 6 **Papadimitrakopoulou, V. – Gadgeel, S. M. – Borghaei, H., et al.:** First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. 2017 ASCO Annual Meeting. Poster Session (Board #420). *J Clin Oncol*, 2017, 35, suppl, abstrakt 9094.
- 7 **Brahmer, J. R. – Rodriguez-Abreu, D. – Robinson, A. G., et al.:** Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS)  $\geq 50\%$  enrolled in KEYNOTE-024. 2017 ASCO Annual Meeting. *J Clin Oncol*, 2017, 35, suppl, abstrakt 9000.
- 8 **Gandhi, L. – Rodriguez-Abreu, D. – Gadgeel, S., et al.:** Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*, 2018.

## Deficit $\alpha_1$ -antitrypsinu

MUDr. Jan Chlumský, Ph.D. Pneumologická klinika, 1. LF UK a FTN, Praha

- 1 **Stoller, J. K.:** American Thoracic Society/European Respiratory Society Statement. *Am J Respir Crit Care Med*, 2003, 168, s. 818–900, doi:10.1164/rccm.168.7.818.
- 2 **Miravittles, M. – Dirksen, A. – Ferrarotti, I., et al.:** European Respiratory Society statement: diagnosis and treatment of pulmonary disease in  $\alpha_1$ -antitrypsin deficiency. *Eur Respir J*, 2017, 50, 1700610, doi:10.1183/13993003.00610-2017.
- 3 **Vogelmeier, C. F. – Criner, G. J. – Martinez, F. J., et al.:** Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report GOLD Executive Summary. *Eur Respir J*, 2017, 49, 1700214, doi:10.1164/rccm.201701-0218PP.
- 4 **Stoller, J. K. – Aboussouan, L. S.:** A review of  $\alpha_1$ -antitrypsin deficiency. *Am J Respir Crit Care Med*, 2012, 185, s. 246–259, doi:10.1164/rccm.201108-1428CI.
- 5 **Koblížek, V. – Chlumský, J. – Zindr, V., et al.:** Chronic obstructive pulmonary disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthiologische society; a novel phenotypic approach to COPD with patient-oriented care. *Biomed Pap*, 2013, 157, s. 189–201, doi:10.5507/bp.2013.039.
- 6 **Campos, M. A. – Diaz, A. A.:** The role of computed tomography for the evaluation of lung disease in alpha-1 antitrypsin deficiency. *Chest*, 2018, v tisku, doi:10.1016/j.chest.2017.11.017.
- 7 **Chapman, K. R. – Burdon, J. G. W. – Piitulainen, E., et al.:** Intravenous augmentation treatment and lung density in severe  $\alpha_1$ -antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. *Lancet*, 2015, 386, s. 360–368, doi:10.1016/S0140-6736(15)60860-1.
- 8 **McElvaney, N. G. – Burdon, J. – Holmes, M., et al.:** Long-term efficacy and safety of  $\alpha_1$  proteinase inhibitor treatment for emphysema caused by severe  $\alpha_1$  antitrypsin deficiency: an open-label extension trial (RAPID-OLE). *Lancet Respir Med*, 2016, 2600, s. 1–9, doi:10.1016/S2213-2600(16)30430-1.
- 9 **Chapman, K. R. – Chorostowska-Wynimko, J. – Koczulla, A. R., et al.:** Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: Recent developments and clinical implications. *Int J COPD*, 2018, 13, s. 419–432, doi:10.2147/COPD.S149429.

## Triple terapie u chronické obstrukční plicní nemoci

doc. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie a hrudní chirurgie Nemocnice Na Bulovce a 3. LF UK, Praha

- 1 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2018.
- 2 **Singh, D. – Papi, A. – Corradi, M., et al.:** Single inhaler triple therapy versus inhaled corticosteroid plus long-acting  $\beta_2$ -agonist therapy for chronic obstructive pulmonary disease (TRIOLOGY): a double-blind, parallel group, randomised controlled trial. *Lancet*, 2016, 388, s. 963–973.
- 3 **Vestbo, J. – Papi, A. – Corradi, M., et al.:** Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. *Lancet*, 2017, 389, s. 1919–1929.
- 4 **Miravittles, M. – Anzueto, A.:** A new two-step algorithm for the treatment of COPD. *Eur Respir J*, 2017, 49, s. 1602200.
- 5 **Roche, N. – Chapman, K. R. – Vogelmeier, C. F., et al.:** Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial. *Am J Respir Crit Care Med*, 2017, 195, s. 1189–1197.
- 6 **Rabe, K. F. – Beghé, B. – Fabbri, L. M.:** Peripheral eosinophil count as a biomarker for the management of COPD: not there yet. *Eur Respir J*, 2017, 50, s. 1702165.
- 7 **Papi, A. – Vestbo, J. – Fabbri, L., et al.:** Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet*, 2018, 391, s. 1076–1084.
- 8 **Lipson, D. A. – Barnhart, F. – Brealey, N., et al.:** IMPACT Investigators: Once-daily single-inhaler triple versus dual therapy in patients with COPD. *N Engl J Med*, 18. 4. 2018, doi: 10.1056/NEJMoa1713901, Epub před tiskem.
- 9 ClinicalTrials.gov. NCT02465567 (ETHOS) Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02465567>, vyhledáno 8. 4. 2017.

## CHOPN – účinná bronchodilatační léčba – kazuistika

MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha

- 1 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Dostupné z: <http://goldcopd.org>.
- 2 **Koblížek, V., et al.:** Doporučený postup pro diagnostiku a léčbu stabilní CHOPN. ČPFS, 2013, dostupné z: [www.pneumologie.cz](http://www.pneumologie.cz).
- 3 **Roche, N. – Small, M. – Broomfield, S., et al.:** Real World COPD: Association of morning symptoms with clinical and patient reported outcomes. *COPD*, 2013, 10, s. 679–686.
- 4 **Barnes, P. J.:** Distribution of receptor targets in the lung. *Proc Am Thorac Soc*, 2004, 1, s. 345–351.
- 5 **Bártů, V.:** Nová duální kombinace acilidinium bromidu a formoterol fumarátu. *Nemedia*, 2015, 6, s. 392–394.
- 6 **Decramer, M. – Cooper, Ch. B.:** Treatment of COPD: the sooner the better? *Thorax*, 2010, 65, s. 837–841.
- 7 **Bateman, E. D. – Chapman, K. R. – Singh, A., et al.:** Acilidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). *Respir Res*, 2015, 19, s. 1–13.

## Stručné souvislosti vakcinace proti pneumokokovi u nemocných s CHOPN a bronchiálním astmatem

MUDr. Pavel Turčáni Klinika nemocí plicních a tuberkulózy FN a LF MU, Brno

- 1 **Welch, W.:** The Micrococcus lanceolatus, with especial reference to the etiology of acute lobar pneumonia. *Johns Hopkins Hospital Bulletin*, 1892, iii, s. 125–139.
- 2 **Atkinson, W. – Wolfe, C. – Hamborsky, J. (eds.):** *Epidemiology and prevention of vaccine-preventable diseases*. Public Health Foundation, 2012.
- 3 Active Bacterial Core Surveillance (ABCs) report Emerging Infections Program Network Streptococcus pneumoniae. Centers for Disease Control and Prevention 2013. Dostupné z: <http://www.cdc.gov/>, vyhledáno 21. 5. 2018.
- 4 Pneumococcal disease. World Health Organisation 2011. Dostupné z: <http://www.who.int/>, vyhledáno 21. 5. 2018.
- 5 **Wang, I. K. – Lin, C. L. – Lin, P. C., et al.:** Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. *PLoS one*, 2013, 8, s. e58317, PubMed: 23516462.
- 6 **Mor, A. – Thomsen, R. W. – Ulrichsen, S. P., et al.:** Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. *Eur J Intern Med*, 2013, 24, s. 349–353, PubMed: 23510659.
- 7 **Vestbo, J. – Hurd, S. S. – Agustí, A. G., et al.:** Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*, 2013, 187, s. 347–365.
- 8 **Nuorti, J. P. – Butler, J. C. – Farley, M. M., et al.:** Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. *N Engl J Med*, 2000, 342, s. 681–689.
- 9 **Dominguez, A. – Izquierdo, C. – Salleras, L., et al.:** Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. *Eur Respir J*, 2010, 36, s. 608–614.
- 10 **Moberley, S. – Holden, J. – Tatham, D. P., et al.:** Vaccines for preventing pneumococcal infection in adults. *Cochrane Database Syst Rev*, 2013, 1, CD000422.
- 11 **Ramakrishnan, M. – Moisi, J. C. – Klugman, K. P., et al.:** Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. *Lancet Infect Dis*, 2010, 10, s. 329–337.
- 12 **Lujan, M. – Burgos, J. – Gallego, M., et al.:** Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. *Clin*

- Infect Dis*, 2013, 57, s. 1722–1730.
- 13 Musher, D. M. – Watson, D. A. – Dominguez, E. A.: Pneumococcal vaccination: work to date and future prospects. *Am J Med Sci*, 1990, 300, s. 45–52.
  - 14 MacLeod, C. M. – Hodges, R. G.: Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. *J Exp Med*, 1945, 82, s. 445–465.
  - 15 Pneumococcal disease: guidance, data and analysis, Public Health England 2014. Dostupné z: <https://www.gov.uk/>, vyhledáno 21. 5. 2018.
  - 16 Aktürk, Ü. – Görek Dilektaşlı, A. – Şengül, A., et al.: Influenza and pneumonia vaccination rates and factors affecting vaccination among patients with chronic obstructive pulmonary disease. *Balkan Med J*, 2017, 34, s. 206–211.
  - 17 Whitney, C. G. – Farley, M. M. – Hadler, J., et al.: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *New Eng J Med*, 2003, 348, s. 1737–1746.
  - 18 Simonsen, L. – Taylor, R. J. – Young-Xu, Y., et al.: Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. *Mbio*, 2011, 2, s. e00309–e00310.
  - 19 Veloso, M. – do Nascimento, N. H. – Gazzotti, M. R., et al.: Evaluation of effects of shoulder girdle training on strength and performance of activities of daily living in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*, 2013, 8, s. 187–192.
  - 20 Bonten, M. J. – Huijts, S. M. – Bolkenbaas, M., et al.: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med*, 2015, 372, s. 1114–1125.
  - 21 van Eerd, E. A. – van der Meer, R. M. – van Schayck, O. C., et al.: Smoking cessation for people with chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, 2016, 8, CD010744.
  - 22 Centers for Disease Controls Prevention (CDC): Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions; recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*, 2012, 61, s. 816–819.
  - 23 Centers for Disease Controls Prevention (CDC): Pneumococcal Vaccination. Dostupné z: <https://www.cdc.gov/>, vyhledáno 21. 5. 2018.
  - 24 Pneumococcal Disease. Centers for Disease Controls Prevention (CDC) 2017. Dostupné z: <https://www.cdc.gov/>, vyhledáno 21. 5. 2018.
  - 25 2018 Global strategy for prevention, diagnosis and management of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Dostupné z: <http://goldcopd.org/>, vyhledáno 21. 5. 2018.
  - 26 Global strategy for asthma management and prevention. Global Initiative for Asthma 2018. Dostupné z: <http://ginasthma.org/>, vyhledáno 21. 5. 2018.
  - 27 Doporučený postup ČPFS pro diagnostiku a léčbu stabilní CHOPN (revize květen 2016), Česká pneumologická a ftezeologická společnost České lékařské společnosti J. E. Purkyně (ČPFS ČLS JEP). Dostupné z: <http://www.pneumologie.cz/>, vyhledáno 21. 5. 2018.
  - 28 Doporučený postup diagnostiky a léčby bronchiálního astmatu (aktualizace 2016), Česká pneumologická a ftezeologická společnost České lékařské společnosti J. E. Purkyně (ČPFS ČLS JEP). Dostupné z: <http://www.pneumologie.cz/>, vyhledáno 21. 5. 2018.
  - 29 Juthani-Mehta, M. – De, R. N. – Allore, H., et al.: Modifiable risk factors for pneumonia requiring hospitalization of community-dwelling older adults: the Health, Aging, and Body Composition Study. *J Am Geriatr Soc*, 2013, 61, s. 1111–1118.
  - 30 DiSantostefano, R. L. – Li, H. – Hinds, D., et al.: Risk of pneumonia with inhaled corticosteroid/long-acting beta 2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. *Inter Nat J COPD*, 2014, 9, s. 457–468.
  - 31 Kurashima, K. – Takaku, Y. – Nakamoto, K., et al.: Risk factors for pneumonia and the effect of the pneumococcal vaccine in patients with chronic airflow obstruction. *Chron Obstr Pulm Dis*, 2016, 3, s. 610–619.
  - 32 Eon, J. S. – Song, W. J. – Yoo, H., et al.: Chronic obstructive pulmonary disease is associated with severe pneumonia. *Ann Thoracic Med*, 2015, 10, s. 105–111.
  - 33 Almirall, J. – Bolibar, I. – Serra-Prat, M., et al.: New evidence of risk factors for community acquired pneumonia: a population-based study. *Eur Respir J*, 2008, 31, s. 1274–1284.
  - 34 Mullerova, H. – Chigbo, C. – Hagan, G. W., et al.: The natural history of community acquired pneumonia in COPD patients: a population database analysis. *Respir Med*, 2012, 106, s. 1124–1133.
  - 35 Jackson, M. L. – Nelson, J. C. – Jackson, L.A.: Risk factors for community-acquired pneumonia in immunocompetent seniors. *J Am Geriatr Soc*, 2009, 57, s. 882–888.

## Biologicky cílená léčba sarkoidózy – kazuistiky

MUDr. Lýdia Žarnayová | MUDr. Monika Žurková, Ph.D. | prof. MUDr. Vítězslav Kolek, CSc.

Klinika plicních nemocí a tuberkulózy, LF UP a FN Olomouc

- 1 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. *Am J Respir Crit Care Med*, 1999, 160, s. 736–755.
- 2 Schupp, J. Ch. – Freitag-Wolf, S. – Bargagli, E., et al.: Phenotypes of organ involvement in sarcoidosis. *Eur Respir J*, 2018, 51, s. 1700991.
- 3 Baughman, R. P. – Teirstein, A. S., Judson, M. A., et al.: Clinical characteristics of patients in a case control study of sarcoidosis. *Am J Respir Crit Care Med*, 2001, 164, s. 1885–1889.
- 4 Kolek, V.: Epidemiological study on sarcoidosis in Moravia and Silesia. *Sarcoidosis*, 1994, 12, s. 110–112.
- 5 Amin, E. N. – Closser, D. R. – Crouser, E. D.: Current best practice in the management of pulmonary and systemic sarcoidosis. *Ther Adv Respir Dis*, 2014, 8, s. 111–132.
- 6 Korsten, P. – Strohmayer, K. – Baughman, R. P., et al.: Refractory pulmonary sarcoidosis: Proposal of a definition and Recommendation for the Diagnostic and therapeutic approach. *Clin Pulm Med*, 2016, 23, s. 67–75.
- 7 Baughman, R. P. – Grutters, J. C.: New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. *Lancet Resp Med*, 2015, 3, s. 813–822.
- 8 Callejas-Rubio, J. L. – López-Pérez, L. – Ortego-Centeno, N.: Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. *Ther Clin Risk Manag*, 2008, 4, s. 1305–1313.
- 9 Baughman, R. P. – Drent, M. – Kavuru, M., et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. *Am J Respir Crit Care Med*, 2006, 174, s. 795–802.
- 10 Rossman, M. D. – Newman, L. S. – Baughman, R. P., et al.: A double-blind, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis*, 2006, 23, s. 201–208.
- 11 Judson, M. A. – Baughman, R. P. – Costabel, U., et al.: Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomized trial. *Eur Respir J*, 2008, 1189–1196.
- 12 Hostettler, K. E. – Studler, U. – Tamm, M., et al.: Long-term treatment with infliximab in patients with sarcoidosis. *Respiration*, 2012, 83, s. 218–222.
- 13 Sweiss, N. J. – Barnathan, E. S. – Lo, K. – Judson, M. A. – Baughman R.: C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis*, 2010, 27, s. 49–56.

## CHOPN – kardiální pacient – kombinace bronchodilatancií – studie CLAIM

MUDr. Jan Beneš Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

- 1 Global initiative for chronic obstructive lung disease (GOLD). 2017.
- 2 Wedzicha, J. A. – Banerji, D. – Chapman, K. R., et al.: Indacaterol-glycopyrronium versus salmeterol-fluticasone for copd. *New Eng J Med*, 2016, 374, s. 2222–2234.
- 3 Hohlfeld, J. M. – Vogel-Claussen, J. – Biller, H., et al.: Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and copd (claim): A double-blind, randomised, crossover, placebo-controlled, single-centre trial. *Lancet Resp Med*, 2018, 6, s. 368–378.
- 4 Paulus, W. J. – Tschope, C.: A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol*, 2013, 62, s. 263–271.

## Účinnost duální bronchodilatační léčby (indakaterol/glykopyrronium) na snížení plicní hyperinflace a následné zlepšení plnění komor u pacientů s CHOPN – komentář ke studii CLAIM

MUDr. Milan Sova, Ph.D. Klinika plicních nemocí a TBC, FN Olomouc

- 1 Hohlfeld, J. M. – Vogel-Claussen, J. – Biller, H., et al.: Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. *Lancet Respir Med*, 2018, 6, s. 368–378.
- 2 Casanova, C. – Cote, C. – de Torres, J. P., et al.: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2005, 171, s. 591–597.
- 3 Tzani, P. – Aiello, M. – Elia, D., et al.: Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients. *Respir Res*, 2011, 12, s. 150.
- 4 Vogelmeier, C. F. – Criner, G. J. – Martinez, F. J., et al.: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med*, 2017, 195, s. 557–582.
- 5 Beeh, K. M. – Singh, D. – Di Scala, L. – Drollmann, A.: Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. *Int J Chron Obstruct Pulmon Dis*, 2012, 7, s. 503–513.
- 6 Santus, P. – Radovanovic, D. – Di Marco, S., et al.: Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. *Int J Chron Obstruct Pulmon Dis*, 2015, 10, s. 1917–1923.
- 7 Stone, I. S. – Barnes, N. C. – James, W. Y., et al.: Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial. *Am J Respir Crit Care Med*, 2016, 193, s. 717–726.



# Význam lehkých exacerbací CHOPN

MUDr. Jaromír Zatloukal, Ph.D. Klinika plicních nemocí a tuberkulózy, FN a LF UP Olomouc

- 1 Vogelmeier, C. F., et al.: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med*, 2017, 195, s. 557–582.
- 2 Anthonisen, N. R. – Manfreda, J. – Warren, C., et al.: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med*, 1987, 106, s. 196–204.
- 3 Wedzicha, J. A. – Decramer, M. – Ficker, J. H., et al.: Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. *Lancet Respir Med*, 2013, 1, s. 199–209.
- 4 Wedzicha, J. A. – Banerji, D. – Chapman, K. R., et al.: Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. *N Engl J Med*, 2016, 374, s. 2222–2234.
- 5 Hurst, J. R. – Vestbo, J. – Anzueto, A., et al.: Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med*, 2010, 363, s. 1128–1138.
- 6 Sato, M. – Chubachi, S. – Sasaki, M., et al.: Impact of mild exacerbation on COPD symptoms in a Japanese cohort. *International Journal of COPD*, 2016, 11, s. 1269–1278.
- 7 Suissa, S. – Dell’Aniello, S. – Ernst, P.: Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. *Thorax*, 2012, 67, s. 957–963.
- 8 Dal Negro, R. W. – Wedzicha, J. – Iversen, M., et al.: Effect of erdo- steine on the rate and duration of COPD exacerbations: the RESTORE study. *Eur Respir J*, 2017, 50, 1700711.

# Bronchiectazie – dělení, diagnostika a léčba

MUDr. Petr Jakubec, Ph.D. Klinika plicních nemocí a tuberkulózy FN a LF UP, Olomouc

- 1 Katzenstein, A. L.: Nonspecific inflammatory and destructive disease. In: Katzenstein, A. L. (ed.): *Katzenstein and Askins's Surgical Pathology of Non-Neoplastic Lung Disease*. Philadelphia, W.B. Saunders, 1997, s. 422–425.
- 2 Wynn-Williams, N.: Bronchiectasis: a study centred on Bedford and its environs. *Br Med J*, 1953, 1, s. 1194–1199.
- 3 Säynäjängas, O. – Keistinen, T. – Tuuponen, T., et al.: Bronchiectasis in Finland: trends in hospital treatment. *Respir Med*, 1997, 91, s. 395–398.
- 4 Weycker, D. – Edelsberg, J. – Oster, G., et al.: Prevalence and economic burden of bronchiectasis. *Clin Pulm Med*, 2005, 12, s. 205–209.
- 5 Kolek, V. – Kašák, V. – Vašáková, M.: *Pneumologie*. Praha, Maxdorf, 2014.
- 6 Wilson, R.: The Past – The Renaissance of Bronchiectasis. In: 1<sup>st</sup> World Bronchiectasis Conference Joining forces for a breakthrough in bronchiectasis, Abstract book, Hannover, Německo, 2016, dostupné z: [http://world-bronchiectasis-conference.com/fileadmin/user\\_upload/05\\_presse/2016/Abstract\\_Book\\_WBC\\_2016-07-07-09.pdf](http://world-bronchiectasis-conference.com/fileadmin/user_upload/05_presse/2016/Abstract_Book_WBC_2016-07-07-09.pdf), vyhledáno 10. 10. 2016.
- 7 Rademacher, J. – Welte, T.: Bronchiectasis – diagnosis and treatment. *Dtsch Arztebl Int*, 2011, 108, s. 809–815.
- 8 Li, A. M. – Sonnapa, S. – Lex, C., et al.: Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? *Eur Respir J*, 2005, 26, s. 8–14.
- 9 Shoemark, A. – Ozerovitch, L. – Wilson, R.: Aetiology in adult patients with bronchiectasis. *Respir Med*, 2007, 101, s. 1163–1170.
- 10 Pasteur, M. C. – Helliwell, S. M. – Houghton, S. J., et al.: An investigation into causative factors in patients with bronchiectasis. *Am J Respir Crit Care Med*, 2000, 162, s. 1277–1284.
- 11 Martínez-García, M. A. – de Gracia, J. – Relat, M. V., et al.: Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. *Eur Respir J*, 2014, 43, s. 1357–1367.
- 12 Chalmers, J. – Goeminne, P. – Aliberti, S., et al.: The Bronchiectasis Severity Index. *Am J Respir Crit Care Med*, 2014, 189, s. 576–585.
- 13 Chu, H. – Zhao, L. – Xiao, H., et al.: Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis. *Arch Med Sci*, 2014, 10, s. 661–668.
- 14 Gao, Y. H. – Guan, W. J. – Xu, G., et al.: The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: a prospective study. *Chest*, 2015, 147, s. 1635–1643.
- 15 Chalmers, J. D. – Aliberti, S. – Blasi, F.: Management of bronchiectasis in adults. *Eur Respir J*, 2015, 45, s. 1446–1462.
- 16 Polverino, E. – Goeminne, P. C. – McDonnell, M. J., et al.: European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J*, 2017, 50, s. 1700629; DOI: 10.1183/13993003.00629-2017.
- 17 Kellett, F. – Robert, N. M.: Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. *Respir Med*, 2011, 105, s. 1831–1835.
- 18 Bilton, D. – Daviskas, E. – Anderson, D., et al.: Phase 3 randomised study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. *Chest*, 2013, 144, s. 215–225.
- 19 Bilton, D. – Tino, G. – Barker, A. F., et al.: Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. *Thorax*, 2014, 69, s. 1073–1079.
- 20 Wilkinson, M. – Sugumar, K. – Milan, S. J., et al.: Mucolytics for bronchiectasis. *Cochrane Database Syst Rev*, 2014, 5, s. CD001289.
- 21 Neumannová, K. – Zatloukal, J. – Koblížek, V.: Doporučený postup plicní rehabilitace. Dostupné z: <http://www.pneumologie.cz/guidelines/>, vyhledáno 20. 4. 2018.
- 22 Lee, A. L. – Hill, C. J. – McDonald, C. F., et al.: Pulmonary rehabilitation in individuals with non-cystic fibrosis bronchiectasis: a systematic review. *Arch Phys Med Rehabil*, 2017, 98, s. 774–782. e1, doi: 10.1016/j.apmr.2016.05.017, Epub 16. 6. 2016.
- 23 Pryor, J. A.: Physiotherapy for airway clearance in adults. *Eur Respir J*, 1999, 14, s. 1418–1424.
- 24 Wu, Q. – Shen, W. – Cheng, H., et al.: Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. *Respirology*, 2014, 19, s. 321–329.
- 25 Goyal, V. – Chang, A. B.: Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. *Cochrane Database Syst Rev*, 2014, 10, s. CD010327, doi: 10.1002/14651858.CD010327.pub2.
- 26 Henkle, E. – Aksamit, T. R. – Barker, A. F., et al.: Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info&Research Patient Survey and the Bronchiectasis and NTM Research Registry. *Chest*, 2017, 152, s. 1120–1157.
- 27 Holme, J. – Tomlinson, J. W. – Stockley, R. A., et al.: Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. *Eur Respir J*, 2008, 32, s. 1047–1052.
- 28 Kapur, N. – Chang, A. B.: Oral non steroid anti-inflammatories for children and adults with bronchiectasis. *Cochrane Database Syst Rev*, 2007, 17, s. CD006427.
- 29 Bedi, P. – Chalmers, J. D. – Graham, C., et al.: A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with pseudomonas aeruginosa: a proof of concept study. *Chest*, 2017, 152, s. 368–3678.
- 30 Balkanli, K. – Genç, O. – Dakak, M., et al.: Surgical management of bronchiectasis: analysis and short-term results in 238 patients. *Eur J Cardiothorac Surg*, 2003, 24, s. 699–702.

# (Ne)novinky v léčbě idiopatické plicní fibrózy

MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 Fisher, M. – Nathan, S. D. – Hill, C., et al.: Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. *J Manag Care Spec Pharm*, 2017, 23, suppl, S17–S24.
- 2 Shaw, J. – Marshall, T. – Morris H., et al.: Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age. *J Thorac Dis*, 2017, 9, s. 4700–4707.
- 3 Vašáková, M.: Idiopatická plicní fibróza – doporučený postup pro diagnózu, léčbu a sledování, dostupné z: [www.pneumologie.cz/upload/1372941097.pdf](http://www.pneumologie.cz/upload/1372941097.pdf), vyhledáno 28. 4. 2018.
- 4 Magruder, J. T. – Crawford, T. C. – Grimm, J. C., et al.: Risk factors for de novo malignancy following lung transplantation. *Am J Transplant*, 2017, 17, s. 227–238.
- 5 Thabut, G. – Mal, H.: Outcomes after lung transplantation. *J Thorac Dis*, 2017, 9, s. 2684–2691.
- 6 Stella, G. M. – Balestro, E. – Lacedonia, D., et al.: Telomeropathies: an emerging spectrum of disorders with important implications for patients with interstitial lung disease. *Minerva Med*, 2016, 107, suppl. 1, s. 9–14.
- 7 Fernández, A. B. – Karas, R. H. – Alsheikh-Ali, A. A., et al.: Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. *Chest*, 2008, 134, s. 824–830.
- 8 Vedel-Krogh, S. – Nielsen, S. F. – Nordestgaard, B. G.: Statin use is associated with reduced mortality in patients with interstitial lung disease. *PLoS One*, 2015, 10, s. e0140571.
- 9 Kreuter, M. – Bonella, F. – Maher, T. M., et al.: Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. *Thorax*, 2017, 72, s. 148–153.
- 10 Wells, A. U. – Behr, J. – Costabel, U., et al.: Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. *Eur Respir J*, 2012, 39, s. 805–806.
- 11 Kreuter, M. – Wijsenbeek, M. S. – Vasakova, M., et al.: Un favourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. *Eur Respir J*, 2016, 47, s. 1776–1784.
- 12 Collum, S. D. – Amione-Guerra, J. – Cruz-Solbes, A. S., et al.: Pulmonary hypertension associated with idiopathic pulmonary fibrosis: current and future perspectives. *Can Respir J*, 2017, 2017, s. 1430350.
- 13 Vainshelboim, B. – Kramer, M. R. – Fox, B. D., et al.: Supervised exercise training improves exercise cardiovascular function in idiopathic pulmonary fibrosis. *Eur J Phys Rehabil Med*, 2017, 53, s. 209–218.
- 14 Visca, D. – Tsiopouri, V. – Mori, L., et al.: Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. *Trials*, 2017, 18, s. 201.
- 15 Ryerson, C. J. – Camp, P. G. – Eves, N. D., et al.: High oxygen delivery to preserve exercise capacity in patients with idiopathic pulmonary fibrosis treated with nintedanib. Methodology of the HOPE-IPF Study. *Ann Am Thorac Soc*, 2016, 13, s. 1640–1647.
- 16 Biring, S. S. – Wijsenbeek, M. S. – Agrawal, S., et al.: A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. *Lancet Respir Med*, 2017, 5, s. 806–815.

# Současný pohled na diagnostický význam vydechovaného oxidu dusnatého

doc. MUDr. Petr Čáp, Ph.D. Centrum alergologie a klinické imunologie Nemocnice Na Homolce, Praha

- 1 Dweik, R. A. – Boggs, P. B. – Erzurum, S. C., et al.: American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications: An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med*, 2011, 184, s. 602–615.
- 2 Wang, Z. – Pianosi, P. – Keogh, K., et al.: The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Comparative Effectiveness Review No. 197 (Prepared by the Mayo Clinic Evidence-based Practice Center under Contract No. 290-2015-00013-I). AHRQ Publication No.17(18)-EHC030-EF. Rockville, MD: Agency for Healthcare Research and Quality. December 2017. Dostupné z: [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm), DOI: <https://doi.org/10.23970/AHRQEPCCER197>, vyhledáno 28. 5. 2018.
- 3 Čáp, P. – Bencová, A. – Jeseňák, M.: Využití vydechovaného oxidu dusnatého u astma bronchiale. *Mladá fronta*, 2014.

# Biomarkery a biologická léčba bronchiálního astmatu

MUDr. Irena Krčmová, CSc. | MUDr. Jakub Novosad, Ph.D. Ústav klinické imunologie a alergologie FN Hradec Králové

MUDr. Vratislav Sedlák, Ph.D. Plicní klinika FN Hradec Králové a LF UK, Hradec Králové

- Berry, A. – Busse, W. W.: Biomarkers in asthmatic patients: Has their time come to direct treatment? *J Allergy Clin Immunol*, 2016, 137, s. 1317–1324.
- Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group: Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. *J Allergy Clin Immunol*, 2012, 130, s. 647–654.e10.
- Bjerner, L. – Lemiere, C. – Maspero, J., et al.: Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. *Chest*, 2016, 150, s. 789–798. doi:10.1016/j.chest.2016.03.032.
- Bleecker, E. R. – FitzGerald, J. M. – Chanez, P., et al.: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2agonists (SIRIOCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*, 2016, 388, s. 2115–2127. doi:10.1016/S0140-6736(16)31324-1.
- Brightling, C. E. – Chanez, P. – Leigh, R., et al.: Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet Respir Med*, 2015, 3, s. 692–701.
- Brusselle, G. G. – Vanderstichele, C. – Jordens, P., et al.: Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo controlled trial. *Thorax*, 2013, 68, s. 322–329.
- Busse, W. W. – Holgate, S. – Kerwin, E., et al.: Randomized, double-blind, placebo controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. *Am J Respir Crit Care Med*, 2013, 188, s. 1294–1302.
- Castro, M. – Zangrilli, J. – Wechsler, M. E., et al.: Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicenter, parallel, double-blind, randomized, placebo controlled, phase 3 trials. *Lancet Respir Med*, 2015, 3, s. 355–366.
- Chung, K. F. – Wenzel, S. E. – Brozek, J. L., et al.: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*, 2014, 43, s. 343–373.
- Chung, K. F.: Targeting the interleukin pathway in the treatment of asthma. *Lancet*, 2015, 386, s. 1086–1096.
- Conway, S. J. – Izuhara, K. – Kudo, Y., et al.: The role of periostin in tissue remodeling across health and disease. *Cell Mol Life Sci*, 2014, 71, s. 1279–1288.
- Corren, J. – Lemanske, R. F. – Hanania, N. A., et al.: Lebrikizumab treatment in adults with asthma. *N Engl J Med*, 2011, 365, s. 1088–1098.
- Corren, J. – Weinstein, S. – Janka, L., et al.: Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. *Chest*, 2016, 150, s. 799–810.
- De Boever, E. H. – Ashman, C. – Cahn, A. P., et al.: Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. *J Allergy Clin Immunol*, 2014, 133, s. 989–996.
- FitzGerald, J. M. – Bleecker, E. R. – Nair, P., et al.: Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*, 2016, 388, s. 2128–2141. doi:10.1016/S0140-6736(16)31322.
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2016. Dostupné z: <http://www.ginaasthma.org>, vyhledáno 15. 5. 2018.
- Haldar, P. – Brightling, C. E. – Singapuri, A., et al.: Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. *J Allergy Clin Immunol*, 2014, 133, s. 921–923.
- Hanania, N. A. – Korenblat, P. – Chapman, K. R., et al.: Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. *Lancet Respir Med*, 2016, 4, s. 781–796. doi:10.1016/S2213-2600(16)30265-X.
- James, A. J. – Reinius, L. E. – Verhoek, M., et al.: BIOAIR (Longitudinal Assessment of Clinical Course and Biomarkers in Severe Chronic Airway Disease) Consortium. Increased YKL-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2016, 193, s. 131–142.
- Krčmová, I. – Novosad, J.: One year follow-up of patients after omalizumab treatment withdrawal. ISAF, 2017, Manchester.
- Kuhl, K. – Hanania, N. A.: Targeting IgE in asthma. *Curr Opin Pulm Med*, 2012, 18, s. 1–5.
- Kuo, C. S. – Pavlidis, S. – Loza, M., et al.: U-BIOPRED Study Group: T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. *Eur Respir J*, 2017, 49, s. 1602135.
- Lefauedeux, D. – De Meulder, B. – Loza, M. J., et al.: U-BIOPRED clinical adult asthma clusters linked to a subset of sputum – omics. *J Allergy Clin Immunol*, 2017, 139, s. 1797–1807.
- Lim, H. F. – Nair, P.: Airway inflammation and inflammatory biomarkers. *Semin Respir Crit Care Med*, 2018, 39, s. 56–63.
- Maes, T. – Joos, G. F. – Brusselle, G. G.: Targeting interleukin-4 in asthma: lost in translation? *Am J Respir Cell Mol Biol*, 2012, 47, s. 261–270.
- Moore, W. C. – Hastie, A. T. – Li, X., et al.: Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. *J Allergy Clin Immunol*, 2014, 133, s. 1557–1563.
- Mukherjee, M. – Nair, P.: Blood or sputum eosinophils to guide asthma therapy? *Lancet Respir Med*, 2015, 3, s. 824–825.
- Nair, P. – O'Byrne, P. M.: Measuring eosinophils to make treatment decisions in asthma. *Chest*, 2016, 150, s. 485–487.
- Noonan, M. – Korenblat, P. – Mosesova, S., et al.: Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. *J Allergy Clin Immunol*, 2013, 132, s. 567–574.
- Normasell, R. – Walker, S. – Milan, S. J., et al.: Omalizumab for asthma in adults and children. *Cochrane Database Syst Rev*, 2014, CD003559.
- Ortega, H. G. – Liu, M. C. – Pavord, I. D., et al.: Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*, 2014, 371, s. 1198–1207.
- Parulekar, A. D. – Diamant, Z. – Hanania, N. A.: Role of T2 inflammation biomarkers in severe asthma. *Curr Opin Pulm Med*, 2016, 22, s. 59–68.
- Pavord, I. D. – Korn, S. – Howarth, P., et al.: Mepolizumab for severe eosinophilic asthma (DREAM): a multi-centre, double blind, placebo-controlled trial. *Lancet*, 2012, 380, s. 651–659.
- Petsky, H. L. – Cates, C. J. – Lasserson, T. J., et al.: A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). *Thorax*, 2012, 67, s. 199–208.
- Petsky, H. L. – Kew, K. M. – Chang, A. B.: Exhaled nitric oxide levels to guide treatment for children with asthma. *Cochrane Database Syst Rev*, 2016, 11, s. CD011439.
- Trivedi, A. – Hall, C. – Hoffman, E. A., et al.: Using imaging as a biomarker for asthma. *J Allergy Clin Immunol*, 2017, 139, s. 1–10.
- Smith, S. G. – Chen, R. – Kjarsgaard, M., et al.: Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. *J Allergy Clin Immunol*, 2016, 137, s. 75–86.e8.
- Slager, R. E. – Otulana, B. A. – Hawkins, G. A., et al.: IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. *J Allergy Clin Immunol*, 2012, 130, s. 516–522; e4.
- Szefer, S. J. – Wenzel, S. – Brown, R., et al.: Asthma outcomes: biomarkers. *J Allergy Clin Immunol*, 2012, 129, s. 9–23.
- Tang, H. – Fang, Z. – Sun, Y., et al.: YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. *Eur Respir J*, 2010, 35, s. 757–760.
- Teřl, M., et al.: *Doporučený postup diagnostiky a léčby bronchiálního astmatu*. Geum, 30. 6. 2015.
- Teřl, M. – Sedlák, V. – Čáp, P., et al.: Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy. *Allergy*, 2017, 72, s. 1279–1287. doi: 10.1111/all.13165, Epub 26. 4. 2017.
- Trevor, J. L. – Deshane, J. S.: Refractory asthma: mechanisms, targets, and therapy. *Allergy*, 2014, 69, s. 817–827.
- Wagener, A. H. – de Nijs, S. B. – Lutter, R., et al.: External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. *Thorax*, 2015, 70, s. 115–120.
- van Rijjt, L. – von Richthofen, H. – van Ree, R.: Type 2 innate lymphoid cells: at the cross-roads in allergic asthma. *Semin Immunopathol*, 2016, 38, s. 483–496.
- Wagener, A. H. – de Nijs, S. B. – Lutter, R., et al.: External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. *Thorax*, 2015, 70, s. 115–120.
- Wedes, S. H. – Wu, W. – Comhair, S. A. A., et al.: Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children. *J Pediatr*, 2011, 159, s. 248–255.e1.
- Wenzel, S. – Castro, M. – Corren, J., et al.: Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet*, 2016, 388, s. 31–44.
- Wenzel, S. – Ford, L. – Pearlman, D., et al.: Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med*, 2013, 368, s. 2455–2466.
- Domingo, Ch.: Overlapping effects of new monoclonal antibodies for severe asthma. *Drugs*, DOI 10.1007/s40265.017-0810-5.

## Proč očkovat proti viru o velikosti 80 nm

MUDr. Ivana Čierna Peterová Pneumologická ambulance, Brandýs nad Labem

- Kolek, V. – Kašák, V. – Vašáková, M., et al.: *Pneumologie*. 3. vydání, Maxdorf, 2017.
- [www.avenier.cz](http://www.avenier.cz)
- [www.vakciny.net](http://www.vakciny.net)
- [www.medicaltribune.cz](http://www.medicaltribune.cz)